Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Organisation › Details

AstraZeneca plc (LSE: AZN)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. *


Period Start 1999-04-05 merged
  Group AstraZeneca (Group)
  Predecessor Zeneca Group Plc
Product Industry pharmaceutical
Persons Person Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
  Person 2 Dunoyer, Marc (AstraZeneca 201311– CFO joined 201303 as EVP Global Portfolio + Product Strategy before GSK)
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street 1 Francis Crick Avenue
Cambridge Biomedical Campus
  City CB2 0AA Cambridge, Cambridgeshire
    Address record changed: 2024-01-05
Basic data Employees I: 50,001 to 100,0 (2022-12-31)
  Currency USD
  Annual sales 44,351,000,000 (revenue, total, consolidated (2022) 2022-12-31)
  Profit 3,293,000,000 (2022-12-31)
  Cash 6,166,000,000 (2022-12-31)
    * Document for »About Section«: AstraZeneca plc. (11/29/22). "Press Release: AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy".
Record changed: 2024-05-05


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

» top